tiprankstipranks
Clearside Biomedical announces 6-month results from OASIS extension study
The Fly

Clearside Biomedical announces 6-month results from OASIS extension study

Clearside Biomedical announced positive results from the Extension Study of its OASIS Phase 1/2a clinical trial of CLS-AX administered by suprachoroidal injection via Clearside’s SCS Microinjector(R) in neovascular age-related macular degeneration participants. These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data. George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer, commented, "We made tremendous progress in 2022 with the commercialization of our first suprachoroidal product by Bausch + Lomb and the positive safety and durability results from our Phase 1/2a OASIS trial. As we advance our CLS-AX wet AMD program with the initiation of our ODYSSEY Phase 2b trial, we continue to build on this significant momentum and will further increase awareness of the broad potential in delivering therapies to the back of the eye using our proprietary SCS platform technology."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on CLSD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles